Cytovance Biologics, a leading contract development and manufacturing organization (CDMO), is strategically advancing in drug development and manufacturing by integrating its expertise with Alcami, a company specializing in liquid and lyophilization sterile filling, packaging, and labeling. The Chief Commercial Officer of Cytovance, Axel Schleyer, emphasizes the excitement within the team about combining Alcami’s proficiency with their own in bulk drug substance development and manufacturing services. This collaboration aims to provide comprehensive support for drug developers from early development through commercial supply, fostering a shared commitment to quality and innovation.
The pharmaceutical landscape is witnessing a surge in promising drug targets, but many developers lack the internal resources for mass manufacturing, hindering progress toward clinical trials. CDMO partners like Cytovance and Alcami play a crucial role in helping these developers meet future commercialization goals. Success in bringing challenging-to-express and difficult-to-produce products to market relies on partnering with experts who possess years of experience and a proven track record in transforming molecules into bulk drug substances for patients in need.
The integration of Alcami’s sterile fill-finish spaces and advanced manufacturing and filling lines into Cytovance’s capabilities expands the options for customers. This enables a smooth transition of bulk products to a validated Current Good Manufacturing Practice (cGMP) partner for advanced clinical and commercial production and packaging. Alcami’s offerings encompass formulation, release and stability testing, vial and syringe filling, and advanced cGMP biostorage, with a successful track record of supporting over 50 commercial product launches.
Both companies are actively coordinating their manufacturing processes and quality systems. Alcami’s CEO, William Humphries, expresses pride in working alongside Cytovance Biologics, stating their combined 77 years of serving the life science industry assures customers a steadfast commitment to pharmacological product quality. This collaboration marks Cytovance’s third publicly announced partnership of the year, following two earlier international collaborations with custom microbial strain development providers, reinforcing its position as a key player in the rapidly evolving pharmaceutical industry.
About Cytovance Biologics
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) offering ingenuity and integrated development services to support large molecule biologics throughout the journey from R&D to regulatory approval. These services include mammalian cell line development, cell banking, microbial strain development, process and analytical development, process characterization, and cGMP manufacturing. The company’s 140,000+ sq. ft. state-of-the-art facilities in America’s Heartland are designed to meet US, EU, and global regulatory requirements. Find out more at https://cytovance.com/.